Roche partners with Otsuka's Astex in $25 million deal to strengthen breast cancer pipeline

Roche's Genentech subsidiary has signed a collaboration with Astex Pharmaceuticals, a unit of Otsuka, that includes a $25 million upfront payment.

The partnership is an early‑stage effort aimed at discovering and developing new therapies for breast cancer, reflecting Roche's intent to broaden its pipeline in this therapeutic area.

Although the cash component is modest, analysts see the deal as a strategic signal of Roche's commitment to expand its breast‑cancer portfolio and to tap Astex's drug‑discovery expertise.